With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
This year’s Ash features numerous duelling anti-BCMA therapies in multiple myeloma, and the first clinical data for JNJ-4528 impress.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Companies like Nanjing Legend and Cellular Biomedicine Group continue to attract major financial endorsement from Western big pharma, but the threat of scandal is…
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.